Published : Aug-2017
No. of Pages : 262
1 Table of Contents 2
1.1 List of Tables 7
1.2 List of Figures 9
2 Migraine: Executive Summary 10
2.1 Migraine Market Will Grow to $8.7 Billion by 2026 11
2.2 Companies Often Target the Underserved Migraine Population 13
2.3 Current Treatments Leave Major Unmet Needs in the Migraine Market 15
2.4 Market Opportunities for New Entrants 16
2.5 Late-Stage Pipeline Drugs Will Be a Key Driver in the Migraine Market 16
2.6 What Do Physicians Think? 17
3 Introduction 22
3.1 Catalyst 22
3.2 Related Reports 22
3.3 Upcoming Related Reports 22
4 Disease Overview 24
4.1 Migraine Classification 24
4.2 Etiology and Pathophysiology 25
4.2.1 Etiology 25
4.2.2 Pathophysiology 26
4.3 Symptoms 27
4.3.1 Premonitory Phase 27
4.3.2 Aura Phase 27
4.3.3 Headache Phase 28
4.3.4 Resolution Phase 29
4.4 Prognosis 29
4.5 Quality of Life 30
5 Epidemiology 31
5.1 Disease Background 31
5.2 Risk Factors and Comorbidities 32
5.3 Global and Historical Trends 34
5.3.1 US 36
5.3.2 5EU 36
5.3.3 Japan 36
5.4 Forecast Methodology 37
5.4.1 Sources 38
5.4.2 Forecast Assumptions and Methods 40
5.5 Epidemiological Forecast for Migraine (2016-2026) 43
5.5.1 Total Prevalent Cases of Migraine 43
5.5.2 Age-Specific Total Prevalent Cases of Migraine 45
5.5.3 Sex-Specific Total Prevalent Cases of Migraine 46
5.5.4 Migraine Cases by Frequency of Occurrences 47
5.6 Discussion 48
5.6.1 Epidemiological Forecast Insight 48
5.6.2 Limitations of Analysis 49
5.6.3 Strengths of Analysis 49
6 Disease Management 50
6.1 Diagnosis Overview 50
6.2 Treatment Overview 51
6.2.1 Treatment Guidelines and Leading Prescribed Drugs 51
6.2.2 Clinical Practice 52
6.2.3 Episodic Migraine 52
6.2.4 Chronic Migraine 54
6.2.5 Non-pharmacological Treatments 56
6.3 US 56
6.4 5EU 59
6.5 Japan 62
7 Competitive Assessment 65
7.1 Overview 65
7.1.1 Maxalt (rizatriptan benzoate) 66
7.1.2 Relpax (eletriptan hydrobromide) 70
7.1.3 Treximet (sumatriptan succinate + sodium naproxen) 75
7.1.4 Sumavel DosePro (sumatriptan succinate) 78
7.1.5 Rizaport (rizatriptan benzoate) 81
7.1.6 Onzetra Xsail (sumatriptan succinate) 85
7.1.7 Other Triptans 90
7.1.8 Botox (onabotulinum toxin A) 105
7.1.9 Antidepressants 109
7.1.10 Anti-epileptics 113
7.1.11 Other Therapeutic Classes 118
8 Unmet Needs and Opportunity Assessment 120
8.1 Overview 120
8.2 Acute Therapies for Patients with, or at Risk of, Cardiovascular Disorders 121
8.2.1 Unmet Need 121
8.2.2 Gap Analysis 122
8.2.3 Opportunity 123
8.3 Lack of Acute Therapies for Patients Unresponsive to Triptan Medication 124
8.3.1 Unmet Need 124
8.3.2 Gap Analysis 125
8.3.3 Opportunity 126
8.4 Physician Education and Diagnosis 127
8.4.1 Unmet Need 127
8.4.2 Gap Analysis 128
8.4.3 Opportunity 129
8.5 Effective and Well-Tolerated Prophylactic Treatments 129
8.5.1 Unmet Need 129
8.5.2 Gap Analysis 131
8.5.3 Opportunity 133
9 Pipeline Assessment 134
9.1 Overview 134
9.2 Clinical Trial Mapping 136
9.2.1 Clinical Trials by Country and Class 136
9.3 Promising Drugs in Clinical Development 137
9.3.1 Lasmiditan (COL-144) 139
9.3.2 Eptinezumab (ALD-403) 146
9.3.3 Fremanezumab (TEV-48125) 153
9.3.4 Galcanezumab (LY2951742) 160
9.3.5 Erenumab (AMG-334) 166
9.3.6 Ubrogepant (MK-1602) 172
9.3.7 Atogepant (AGN241689) 178
9.3.8 SUD-001 184
9.4 Promising Drugs in Early-Stage Development 190
9.5 Other Drugs in Development 190
10 Current and Future Players 191
10.1 Overview 191
10.2 Trends in Corporate Strategy 193
10.3 GlaxoSmithKline 195
10.3.1 Overview 195
10.3.2 Portfolio Assessment 196
10.3.3 SWOT Analysis 197
10.4 Merck & Co. 197
10.4.1 Overview 197
10.4.2 Portfolio Assessment 198
10.4.3 SWOT Analysis 199
10.5 Pfizer 199
10.5.1 Overview 199
10.5.2 Portfolio Assessment 200
10.5.3 SWOT Analysis 201
10.6 Allergan 201
10.6.1 Overview 201
10.6.2 Portfolio Assessment 202
10.6.3 SWOT Analysis 203
10.7 Amgen 203
10.7.1 Overview 203
10.7.2 Portfolio Assessment 204
10.7.3 SWOT Analysis 205
10.8 Eli Lilly 205
10.8.1 Overview 205
10.8.2 Portfolio Assessment 206
10.8.3 SWOT Analysis 207
10.9 Alder Biopharmaceuticals 207
10.9.1 Overview 207
10.9.2 Portfolio Assessment 208
10.9.3 SWOT Analysis 208
10.10 Teva 209
10.10.1 Overview 209
10.10.2 Portfolio Assessment 209
10.10.3 SWOT Analysis 210
11 Market Outlook 211
11.1 Global Markets 211
11.1.1 Forecast 211
11.1.2 Drivers and Barriers - Global Issues 214
11.2 US 214
11.2.1 Forecast 214
11.2.2 Key Events 217
11.2.3 Drivers and Barriers 217
11.3 5EU 218
11.3.1 Forecast 218
11.3.2 Key Events 220
11.3.3 Drivers and Barriers 220
11.4 Japan 221
11.4.1 Forecast 221
11.4.2 Key Events 223
11.4.3 Drivers and Barriers 223
12 Appendix 224
12.1 Bibliography 224
12.2 Abbreviations 237
12.3 Methodology 241
12.3.1 Forecasting Methodology 241
12.3.2 Diagnosed Migraine Patients 241
12.3.3 Percent Drug-Treated Patients 242
12.3.4 Drugs Included in Each Therapeutic Class 242
12.3.5 Launch and Patent Expiry Dates 243
12.3.6 General Pricing Assumptions 244
12.3.7 Individual Drug Assumptions 245
12.3.8 Generic Erosion 253
12.3.9 Pricing of Pipeline Agents 253
12.4 Primary Research - KOLs Interviewed for This Report 255
12.5 Primary Research - Prescriber Survey 256
12.6 About the Authors 257
12.6.1 Analyst 257
12.6.2 Therapy Area Director 257
12.6.3 Epidemiologist 257
12.6.4 Managing Epidemiologist 258
12.6.5 Global Director of Therapy Analysis and Epidemiology 258
12.6.6 Global Head and EVP of Healthcare Operations and Strategy 258
12.7 About GlobalData 260
12.8 Contact Us 260
12.9 Disclaimer 261
1.1 List of Tables
Table 1: Migraine: Key Metrics in the 7MM 10
Table 2: Migraine Classification from the ICHD-3 24
Table 3: Diagnostic Criteria for Migraine with Aura 28
Table 4: Diagnostic Criteria for Migraine without Aura 29
Table 5: Risk Factors and Comorbidities for Migraine 33
Table 6: ICHD-3 Diagnostic Criteria for Migraine 37
Table 7: Total Prevalent Cases of Migraine, Ages ?18 Years, Both Sexes, N, Select Years 2016-2026 44
Table 8: Treatment Guidelines for Migraine 51
Table 9: Most Prescribed Drugs for Migraine by Class in the 7MM, 2016 52
Table 10: Country Profile - US 58
Table 11: Country Profile - 5EU 61
Table 12: Country Profile - Japan 64
Table 13: Product Profile - Maxalt 67
Table 14: Maxalt SWOT Analysis, 2017 69
Table 15: Product Profile - Relpax 72
Table 16: Relpax Efficacy Clinical Trial Results 73
Table 17: Percentage of Patients with Headache Response (Mild or No Headache) 2 Hours Following Treatment 73
Table 18: Relpax SWOT Analysis, 2017 74
Table 19: Product Profile - Treximet 76
Table 20: Treximet SWOT Analysis, 2017 77
Table 21: Product Profile - Sumavel DosePro 79
Table 22: Sumavel DosePro SWOT Analysis, 2017 81
Table 23: Product Profile - Rizaport 83
Table 24: Rizaport SWOT Analysis, 2017 85
Table 25: Product Profile - Onzetra Xsail 87
Table 26: Onzetra Xsail SWOT Analysis, 2017 89
Table 27: Product Profile - Other Triptans 91
Table 28: Triptan SWOT Analysis, 2017 104
Table 29: Product Profile - Botox 107
Table 30: Botox SWOT Analysis, 2017 109
Table 31: Product Profiles - Antidepressants 111
Table 32: Antidepressants SWOT Analysis, 2017 112
Table 33: Product Profiles - Anti-epileptics 115
Table 34: Anti-epileptics SWOT Analysis, 2017 117
Table 35: Product Profile - Other Therapeutic Classes 119
Table 36: Unmet Need and Opportunity in Episodic and Chronic Migraine, 2017 121
Table 37: Migraine Late-Stage Pipeline, 2017 138
Table 38: Comparison of Therapeutic Classes in Development for Migraine, 2016-2026 139
Table 39: Product Profile - Lasmiditan 142
Table 40: Lasmiditan SWOT Analysis, 2017 145
Table 41: Product Profile - Eptinezumab (ALD-403) 148
Table 42: Eptinezumab (ALD-403) SWOT Analysis, 2017 152
Table 43: Product Profile - Fremanezumab (TEV-48125) 155
Table 44: Fremanezumab (TEV-48125) SWOT Analysis, 2017 159
Table 45: Product Profile - Galcanezumab (LY2951742) 162
Table 46: Product Profile - Erenumab (AMG-334) 168
Table 47: Erenumab (AMG-334) SWOT Analysis, 2017 171
Table 48: Product Profile - Ubrogepant (MK-1602) 174
Table 49: Ubrogepant (MK-1602) SWOT Analysis, 2017 177
Table 50: Product Profile - Atogepant (AGN241689) 180
Table 51: Atogepant (AGN241689) SWOT Analysis, 2017 183
Table 52: Product Profile - SUD-001 186
Table 53: SUD-001 SWOT Analysis, 2017 189
Table 54: Drugs in Development for Migraine, 2016 190
Table 55: Key Companies in the Migraine Market in the 7MM, 2016 191
Table 56: GlaxoSmithKline Disease Portfolio Assessment, 2017 197
Table 57: GSK SWOT Analysis, 2017 197
Table 58: Merck's Disease Portfolio Assessment, 2017 199
Table 59: Merck SWOT Analysis, 2017 199
Table 60: Pfizer's Disease Portfolio Assessment, 2017 201
Table 61: Pfizer SWOT Analysis, 2017 201
Table 62: Allergan's Disease Portfolio Assessment, 2017 203
Table 63: Allergan SWOT Analysis, 2017 203
Table 64: Amgen's Disease Portfolio Assessment, 2017 204
Table 65: Amgen SWOT Analysis, 2017 205
Table 66: Eli Lilly's Disease Portfolio Assessment, 2017 206
Table 67: Eli Lilly SWOT Analysis, 2017 207
Table 68: Alder's Disease Portfolio Assessment, 2017 208
Table 69: Alder SWOT Analysis, 2017 208
Table 70: Teva's Disease Portfolio Assessment, 2017 210
Table 71: Teva SWOT Analysis, 2017 210
Table 72: Migraine Market - Global Drivers and Barriers, 2016-2026 214
Table 73: Key Events Impacting Sales for Migraine in the US, 2016-2026 217
Table 74: Migraine Market - Global Drivers and Barriers in the US, 2016-2026 217
Table 75: Key Events Impacting Sales for Migraine in the 5EU, 2016-2026 220
Table 76: Migraine Market - Global Drivers and Barriers in the 5EU, 2016-2026 220
Table 77: Key Events Impacting Sales for Migraine in Japan, 2016-2026 223
Table 78: Migraine Market - Global Drivers and Barriers in Japan, 2016-2026 223
Table 79: Key Historical and Projected Launch Dates for Migraine 243
Table 80: Key Historical and Projected Patent Expiry Dates for Migraine 243
Table 81: High-Prescribing Physicians (non-KOLs) Surveyed, By Country 256
1.2 List of Figures
Figure 1: Global Sales Forecast by Country for Migraine in 2016 and 2026 12
Figure 2: Analysis of the Company Portfolio Gap in Migraine During the Forecast Period 14
Figure 3: Competitive Assessment of the Late-Stage Pipeline Agents Expected to be Licensed for the Treatment of Migraine During the Forecast Period 17
Figure 4: Pathophysiology of a Migraine 26
Figure 5: 7MM, Age-Standardized Total Prevalence of Migraine, Both Sexes, Ages ?18 Years, 2016 35
Figure 6: Sources Used and Not Used in Epidemiological Analysis of Migraine Prevalence 39
Figure 7: Sources Used and Not Used in Epidemiological Analysis of Migraine Frequency 40
Figure 8: 7MM, Age-Specific Total Prevalent Cases of Migraine, Both Sexes, Ages ?18 Years, 2016 45
Figure 9: 7MM, Sex-Specific Total Prevalent Cases of Migraine, Ages ?18 Years, 2016 46
Figure 10: 7MM, Total Prevalent Migraine Cases by Frequency of Occurrences, Both Sexes, Ages ?18 Years, 2016 47
Figure 11: Overview of the Development Pipeline in Migraine. Darkest circle indicates Phase III of development, the lightest circle Phase 135
Figure 12: Migraine Clinical Trials by Class and Country 136
Figure 13: Migraine Clinical Trials for Drugs in the Late-Stage Pipeline 137
Figure 14: A Competitive Assessment of the Late-Stage Pipeline Agents in Development for the Treatment of Migraine for 2016-2026 138
Figure 15: Clinical and Commercial Positioning of Lasmiditan (COL-144) 144
Figure 16: Clinical and Commercial Positioning of Eptinezumab (ALD-403) 151
Figure 17: Clinical and Commercial Positioning of Fremanezumab (TEV-48125) 158
Figure 18: Clinical and Commercial Positioning of Galcanezumab (LY2951742) 165
Figure 19: Clinical and Commercial Positioning of Erenumab (AMG-334) 170
Figure 20: Clinical and Commercial Positioning of Ubrogepant (MK-1602) 176
Figure 21: Clinical and Commercial Positioning of Atogepant (AGN241689) 182
Figure 22: Clinical and Commercial Positioning of SUD-001 188
Figure 23: Global Sales of Branded Products for Migraine by Company in 2016 and 2026 192
Figure 24: Analysis of the Company Portfolio Gap in Migraine During the Forecast Period 193
Figure 25: Global (7MM) Sales Forecast by Country for Migraine in 2016 and 2026 213
Figure 26: Sales Forecast by Class for Migraine in the US in 2016 and 2026 216
Figure 27: Sales Forecast by Class for Migraine in the 5EU in 2016 and 2026 219
Figure 28: Sales Forecast by Class for Migraine in Japan in 2016 and 2026 222
